GC LabCell, a biotechnology company, to merge with GC Cell, a company specializing in cell therapy. Under the terms of merger agreement, each share of GC Cell stock will be exchanged for a fixed ratio of 0.4 shares of GC LabCell stock. “The new co. will have a nearly ideal blend of business portfolios in the competitive field of cell therapy. Our similar cultures and histories of driving innovation in order to bring more effective and safer therapies to as many patients as possible make this integration a perfect strategic fit,” GC Cell.